The formation of strategic partnerships is an important component of Liquidia’s short- and long-term plans to accelerate PRINT®-enabled therapies into commercial use. Liquidia seeks collaborations with global and regional biopharmaceutical leaders, emerging biotech companies and leading academic institutions. Liquidia and its partners come together to create products that solve problems that current therapies can’t address.
In June 2012, Liquidia entered a broad, multi-year collaboration with GlaxoSmithKline (GSK), which acquired exclusive rights to research and develop certain inhaled therapies using Liquidia’s PRINT technology. In September 2015, GSK exercised its option to exclusively license the right to research, develop, and commercialize inhaled therapeutics based on Liquidia’s PRINT technology. Through this collaboration, Liquidia and GSK will continue to work together with the goal of advancing inhaled therapeutics into clinical studies.
In November 2013, Liquidia established an independent, venture-backed company, Envisia Therapeutics, to leverage PRINT technology in ophthalmology. Envisia’s lead program, ENV515, is a novel extended-release formulation of a prostaglandin analogue for glaucoma, which is currently being evaluated in phase 2 clinical studies.
Liquidia is applying its novel PRINT technology across multiple therapeutic areas.